Navigation Links
Digirad Corporation Appoints John W. Sayward to Its Board of Directors
Date:3/19/2008

POWAY, Calif., March 19 /PRNewswire-FirstCall/ -- Digirad Corporation (Nasdaq: DRAD), a leading provider of medical diagnostic imaging products and services to physicians' offices, hospitals and imaging centers, today announced its board of directors has appointed veteran healthcare executive John W. Sayward director and audit committee chairman, effective immediately.

Mr. Sayward, 56, has more than 30 years of finance, accounting, operational and administrative experience in the healthcare industry, and has previously served on the board of a public pharmaceuticals company. He replaces Raymond Dittamore, 65, who resigned from the board and has retired from business. Mr. Dittamore joined the Digirad board in March 2004 and served as chairman of the audit committee.

Digirad Chairman R. King Nelson said, "John Sayward's extensive operational and financial management background in healthcare and his experience in cardiology will be valuable assets to Digirad as the Company moves forward with its Centers of Excellence expansion strategy and focuses on accelerating its top and bottom line growth.

"We would also like to thank Ray for his many years of providing solid guidance and support of Digirad, and we wish him the very best," King added.

From September 2005 to January 2007, Mr. Sayward was a partner at Nippon Heart Hospital, LLC (NHH), a healthcare management company, formed to partner with leading cardiologists to improve cardiovascular care and build and manage cardiovascular-care hospitals in Japan. While at NHH, Mr. Sayward helped develop relationships with cardiology leaders, government officials and hospital administrators, managed NHH's strategic business plan and evaluated alternatives for financing that plan. From 2002 to 2005, he was executive vice president and chief financial officer of LMA North America Inc., a medical device company, where he managed the company's operations, quality and human resources functions and was a key player in the company's initial public offering.

Prior to 2002, he was chief financial officer and a director of SICOR, Inc., a $2.5 billion pharmaceuticals company that was acquired by Teva Pharmaceuticals. As a senior executive at SICOR he made significant contributions to a highly successful business turnaround and managed a number of corporate-level transactions including the divestiture of a subsidiary, an acquisition and secured financing for strategic expansion.

Mr. Sayward received his undergraduate degree from Northwestern University and a master of management degree from Kellogg School of Management at Northwestern University.

About Digirad Corporation

Digirad provides diagnostic medical imaging products and services to physicians' offices, hospitals and imaging centers for cardiac, vascular, and general imaging applications. Digirad's Cardius XPO line of nuclear imaging cameras use patented solid-state technology and unique multi (single, dual, triple) head design for superior performance and advanced features for sharper digital images, faster processing, compact size, lighter weight for portability, ability to handle patients up to 500 pounds, and improved patient comfort compared to standard nuclear cameras. Digirad's 2020tc general-purpose nuclear imager has a small footprint and may also be configured for fixed or mobile use to supplement primary imaging. Digirad's installed base of equipment exceeds 450 systems; in addition, a mobile fleet of more than 120 nuclear and ultrasound imaging systems is being used in 22 states, primarily in the eastern, midwestern and southwestern United States. For more information, please visit http://www.digirad.com. Digirad(R), Digirad Imaging Solutions(R), and Cardius(R) are registered trademarks of Digirad Corporation.

Forward-Looking Statements

Digirad cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts and use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" and other words and terms of similar meaning in connection with a discussion of future operating or financial performance or events. Examples of such statements include statements regarding the Company's centers of influence expansion strategy and top and bottom line growth projections. The inclusion of these and other forward-looking statements should not be regarded as a representation by Digirad that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Digirad's business, market conditions, overall business prospects and operations; and other risks detailed in Digirad's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Form 8-K and other reports. Given these uncertainties, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Digirad undertakes no obligation to revise or update this press release including the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Investor Contact: Company Contact:

Dan Matsui Mark Casner

Allen & Caron CEO

949-474-4300 858-726-1600

d.matsui@allencaron.com ir@digirad.com


'/>"/>
SOURCE Digirad Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Digirad Corporation to Release Third Quarter, Nine-Month Financial Results on October 25, 2007
2. Digirad Corporation Named to Deloitte Technology Fast 50
3. Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results
4. Digirad Corporation and The Methodist Hospital in Houston Sign Letter of Agreement
5. Digirad Corporation Board of Directors Appoints R. King Nelson Chairman
6. Digirad to Introduce New Clinical Standard for Cardiac SPECT
7. Digirad Corporation to Release Fourth Quarter, Year-End Financial Results on February 7, 2008
8. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
9. Brooke Franchise Corporation Announces Selected July Results
10. MedThink Communications Retained by NanoBio Corporation
11. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology: